With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.80636-30-2,3,3-Dimethyl-3,4-dihydroquinoxalin-2(1H)-one,as a common compound, the synthetic route is as follows.
80636-30-2, EXAMPLE 94 Ethyl 4,5-Dihydro-4,4-dimethylimidazo[1,5-a]quinoxaline-3-carboxylate (XXXIII) Potassium tert-butoxide (1M, 4.54 ml) is added to 1,2,3,4-tetrahydro-3,3-dimethylquinoxalin-2-one (IV, EXAMPLE 2, 0.762 g) in THF (4 ml) at ice/saline temperature. The reaction is stirred for 40 min, at which time diethyl chlorophosphate (0.656 ml) is added. After stirring at ice-saline temperature for 2 hr, ethyl isocyanoacetate (0.562 g) is added, followed by potassium t-butoxide (1 M, 4.97 ml). The reaction is stirred for 3.5 hr, allowing it to slowly warm to 20-25. The reaction is then quenched with several drops of acetic acid and then partitioned between ethyl acetate, aqueous sodium bicarbonate and saline. The phases are separated and the organic phase is dried over magnesium sulfate, concentrated, and the resulting crude product chromatographed on silica gel (200 ml) eluding with methanol/dichloromethane (2/98). The appropriate fractions are pooled and concentrated to give the title compound, mp 145-149; NMR (CDCl3) 1.44, 1.74, 3.79, 4.40, 6.77, 6.82, 7.10, and 7.39 delta.
The synthetic route of 80636-30-2 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; The Upjohn Company; US5541324; (1996); A;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider